Test your knowledge on treatment and management of mTNBC

Which of the following adverse events is the most common endocrinopathy following treatment with anti-PD-L1 monotherapy?

Graves' disease

Adrenal insufficiency

Hypothyroidism

Diabetes mellitus

Sacituzumab govitecan received approval in the USA for treating patients with mTNBC following at least 2 prior therapies in the metastatic setting.

True

False

How is cardiotoxicity defined?

Decline in LVEF of 10% to a final value of under 40%

Decline in LVEF of 15% to a final value of under 33%

Decline in LVEF of at least 10% to a final value of under 50%

Decline in LVEF of 15% to a final value of under 53%

Which of the following therapies would you administer prior to infusion with sacituzumab govitecan?

Single-agent antiemetic, antibiotic, antipyretic

Antibiotic, antiemetic, H2 blocker

Antiemetic, H2 blocker, steroid

Combination antiemetics, antipyretic, H2 blocker

Which of the following regimens are recommended as a second-line therapy for patients with a known germline BRCA mutation and no PD-L1 expression?

Single-agent chemotherapy

Single-agent chemotherapy and olaparib

Pembrolizumab

Olaparib

Of the following, who is at the greatest risk of developing TNBC?

Postmenopausal Latin women

Postmenopausal Caucasian women

Premenopausal Native American women

Premenopausal African American women

In the KEYNOTE-355 study, which of the following agents demonstrated a relative 27% decrease in the risk of death vs chemotherapy alone for patients with mTNBC whose tumors were strongly positive for PD-L1?

Atezolizumab and chemotherapy

Sacituzumab govitecan

Pembrolizumab and chemotherapy

Pembrolizumab alone

Approximately how many patients with mTNBC develop brain metastases?

1/12

1/5

1/3

None of these

Which of the following adverse events is associated with olaparib? (Choose all that apply)

Nephritis with renal dysfunction

Myelodysplastic syndrome

Disseminated intravascular coagulation

Which trial showed that trastuzumab deruxtecan improved progression-free survival and overall survival in patients with HER2-low metastatic breast cancer?

CAPItello-292

SERENA-1

DESTINY-Breast04

CERTIS1